Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ANIXA BIOSCIENCES INC (ANIX) Stock Price & Overview
NASDAQ:ANIX • US03528H1095
Current stock price
3.075 USD
+0.08 (+2.5%)
Last:
The current stock price of ANIX is 3.075 USD. Today ANIX is up by 2.5%. In the past month the price increased by 10.29%. In the past year, price increased by 7.91%.
ANIX Key Statistics
52-Week Range2.44 - 5.4566
Current ANIX stock price positioned within its 52-week range.
1-Month Range2.55 - 3.17
Current ANIX stock price positioned within its 1-month range.
- Market Cap
- 103.105M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.33
- Dividend Yield
- N/A
ANIX Stock Performance
Today
+2.5%
1 Week
-1.32%
1 Month
+10.29%
3 Months
-1.32%
Longer-term
6 Months -27.36%
1 Year +7.91%
2 Years +1.01%
3 Years -26.47%
5 Years -38.52%
10 Years N/A
ANIX Stock Chart
ANIX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ANIX. When comparing the yearly performance of all stocks, ANIX turns out to be only a medium performer in the overall market: it outperformed 46.19% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ANIX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANIX. While ANIX has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ANIX Earnings
Next Earnings DateMay 26, 2026
Last Earnings DateMar 9, 2026
PeriodQ1 / 2026
EPS Reported-$0.08
Revenue Reported
EPS Surprise 17.44%
Revenue Surprise %
ANIX Forecast & Estimates
10 analysts have analysed ANIX and the average price target is 10.2 USD. This implies a price increase of 231.71% is expected in the next year compared to the current price of 3.075.
Analysts
Analysts82
Price Target10.2 (231.71%)
EPS Next Y4.99%
Revenue Next YearN/A
ANIX Index Membership
ANIX is currently included in the following stock indexes tracked on ChartMill.
ANIX Financial Highlights
Over the last trailing twelve months ANIX reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 15.38% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-10.31M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.67% | ||
| ROE | -68.37% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%20%
Sales Q2Q%N/A
EPS 1Y (TTM)15.38%
Revenue 1Y (TTM)N/A
ANIX Ownership
Ownership
Inst Owners15.3%
Shares33.53M
Float31.14M
Ins Owners2.49%
Short Float %3.35%
Short Ratio9.88
ANIX Industry Overview
ANIX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 23.0
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.2
ANIX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.67 | 373.774B | ||
| AMGN | AMGEN INC | 13.7 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.78 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.77 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 28.72 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.5 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 25.042B | ||
| INCY | INCYTE CORP | 10.53 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANIX
Company Profile
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
Company Info
IPO: 1983-10-07
ANIXA BIOSCIENCES INC
3150 Almaden Expy Ste 250
San Jose CALIFORNIA 95118 US
CEO: Amit Kumar
Employees: 4
Phone: 14087089808
ANIXA BIOSCIENCES INC / ANIX FAQ
Can you describe the business of ANIXA BIOSCIENCES INC?
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
What is the stock price of ANIXA BIOSCIENCES INC today?
The current stock price of ANIX is 3.075 USD. The price increased by 2.5% in the last trading session.
Does ANIX stock pay dividends?
ANIX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANIX stock?
ANIX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy ANIX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ANIX.
Can you provide the market cap for ANIXA BIOSCIENCES INC?
ANIXA BIOSCIENCES INC (ANIX) has a market capitalization of 103.10M USD. This makes ANIX a Micro Cap stock.
What is the next earnings date for ANIX stock?
ANIXA BIOSCIENCES INC (ANIX) will report earnings on 2026-05-26.